Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies

(2020) David W. Scott et al.   Frontiers in Immunology

Engineering Immune Tolerance with Biomaterials

(2019) Joshua M. Gammon et al.   Advanced Healthcare Materials

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models

(2019) Yasmin Leshem et al.   Toxins

Antigen-specific therapeutic approaches for autoimmunity

(2019) Pau Serra et al.   NATURE BIOTECHNOLOGY

Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer

(2019) James B. Wing et al.   IMMUNITY

Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins

(2018) Ronit Mazor et al.   AMERICAN JOURNAL OF PATHOLOGY

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

(2018) Robert J. Kreitman et al.   LEUKEMIA

Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity

(2018) Ronit Mazor et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins

(2018) Zuben E. Sauna et al.   TRENDS IN BIOTECHNOLOGY

Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis

(2018) Robert A. LaMothe et al.   Frontiers in Immunology

Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance

(2018) Takashi Kei Kishimoto et al.   Frontiers in Immunology

An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease

(2018) Zoheb B. Kazi et al.   GENETICS IN MEDICINE

Overcoming challenges in treating autoimmuntity: Development of tolerogenic immune-modifying nanoparticles

(2018) Ryan M Pearson et al.   Nanomedicine-Nanotechnology Biology and Medicine

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration

(2018) Amine Meliani et al.   Nature Communications

Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current progress in innovative engineered antibodies

(2017) William R. Strohl   Protein & Cell

Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape

(2017) Federico Mingozzi et al.   Annual Review of Virology

Adalimumab in the Treatment of Immune-Mediated Diseases

(2017) G. Lapadula et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira®in healthy subjects

(2016) Elizabeth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation

(2016) Ai-Hong Zhang et al.   CELLULAR IMMUNOLOGY

The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline

(2016) L. M. Aledort   HAEMOPHILIA

Immunogenicity of therapeutic recombinant immunotoxins

(2016) Ronit Mazor et al.   IMMUNOLOGICAL REVIEWS

PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs

(2016) Peter L. Turecek et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

The Enigma of Rapamycin Dosage

(2016) S. Mukhopadhyay et al.   MOLECULAR CANCER THERAPEUTICS

Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles

(2016) Takashi K. Kishimoto et al.   Nature Nanotechnology

The aged lymphoid tissue environment fails to support naïve T cell homeostasis

(2016) Bryan R. Becklund et al.   Scientific Reports

Engineering antigen-specific immunological tolerance

(2015) Stephan Kontos et al.   CURRENT OPINION IN IMMUNOLOGY

CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy

(2015) Kathryn L. Berrier et al.   GENETICS IN MEDICINE

Adeno-Associated Virus at 50: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal Perspective

(2015) Eric Hastie et al.   HUMAN GENE THERAPY

T Cell Receptor Cross-Reactivity between Similar Foreign and Self Peptides Influences Naive Cell Population Size and Autoimmunity

(2015) Ryan W. Nelson et al.   IMMUNITY

New FDA Draft Guidance on Immunogenicity

(2014) Ashwin Parenky et al.   AAPS Journal

Once a Treg, always a Treg?

(2014) Deepali V. Sawant et al.   IMMUNOLOGICAL REVIEWS

Lineage stability and phenotypic plasticity of Foxp3+regulatory T cells

(2014) Shohei Hori   IMMUNOLOGICAL REVIEWS

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

(2014) S. R. Lentz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Inhibition of Calcineurin Abrogates While Inhibition of mTOR Promotes Regulatory T Cell Expansion and Graft-Versus-Host Disease Protection by IL-2 in Allogeneic Bone Marrow Transplantation

(2014) Atsushi Satake et al.   PLoS One

Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance

(2014) Roberto A. Maldonado et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

(2014) Peter E Lipsky et al.   ARTHRITIS RESEARCH & THERAPY

Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment

(2014) Duncan Howie et al.   Frontiers in Immunology

Immune responses to AAV vectors: overcoming barriers to successful gene therapy

(2013) F. Mingozzi et al.   BLOOD

Challenges and approaches for the development of safer immunomodulatory biologics

(2013) Jean G. Sathish et al.   NATURE REVIEWS DRUG DISCOVERY

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

(2013) Pauline A. van Schouwenburg et al.   Nature Reviews Rheumatology

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

(2012) Yoav H. Messinger et al.   GENETICS IN MEDICINE

Inhibitors: our greatest challenge. Can we minimize the incidence?

(2012) R. Kruse-Jarres   HAEMOPHILIA

PLGA-based nanoparticles: An overview of biomedical applications

(2012) Fabienne Danhier et al.   JOURNAL OF CONTROLLED RELEASE

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

(2011) Suhrad G. Banugaria et al.   GENETICS IN MEDICINE

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

(2011)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets

(2011) R. D. Michalek et al.   JOURNAL OF IMMUNOLOGY

Induction of tolerance to factor VIII by transient co-administration with rapamycin

(2011) B. MOGHIMI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Long-term Safety and Efficacy Following Systemic Administration of a Self-complementary AAV Vector Encoding Human FIX Pseudotyped With Serotype 5 and 8 Capsid Proteins

(2011) Amit C Nathwani et al.   MOLECULAR THERAPY

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B

(2011) Sushrusha Nayak et al.   Frontiers in Microbiology

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model

(2010) A. Joseph et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Immunogenicity of biologic therapies—we need tolerance

(2010) Charlotte L. M. Krieckaert et al.   Nature Reviews Rheumatology

Recombinant Factor VIIa (Eptacog Alfa)

(2009) Katherine F Croom et al.   BIODRUGS

Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells

(2009) S. NAYAK et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants

(2009) Priya S. Kishnani et al.   MOLECULAR GENETICS AND METABOLISM

Sales of biologics to show robust growth through to 2013

(2009) Michael Goodman   NATURE REVIEWS DRUG DISCOVERY

Differential Responses of Human Regulatory T Cells (Treg) and Effector T Cells to Rapamycin

(2009) Laura Strauss et al.   PLoS One

Nanoparticles target distinct dendritic cell populations according to their size

(2008) Vania Manolova et al.   EUROPEAN JOURNAL OF IMMUNOLOGY